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Rational Design and Real Time, In-Cell Detection
of the Proapoptotic Activity
of a Novel Compound Targeting Bcl-XL
trials, showing promising clinical activity [7–10]. How-
ever, Bcl-2 and Bcl-XL represent challenging antisense
targets, due to the long half-life of these proteins [11].
Also, redundancy among antiapoptotic Bcl-2-family
proteins argues in favor of an approach that could nullify
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We and others recently reported that Gossypol, a con-2 University of California, San Diego
School of Medicine stituent of the cotton plant Gossypium [12], is a potent
inhibitor of Bcl-2 and Bcl-XL [13, 14]. The interaction of9500 Gilman Drive SCRB 102
La Jolla, California 92093 this natural product with Bcl-XL was fully characterized
by means of NMR-based methods and fluorescence
polarization displacement assays [13]. Here, aided by a
model of the docked structure of Gossypol into its tar-Summary
get, Bcl-XL [13], we were able to predict modifications
of the natural product on a rational basis. We show hereAntiapoptotic Bcl-2-family proteins Bcl-2 and Bcl-XL
have been recently validated as drug discovery targets that such modifications lead to the analog Apogossypol,
which lacks the reactive aldehydic groups and displaysfor cancer. Here, by using a combination of molecular
modeling, NMR-based structural analysis, fluores- a proapoptotic activity comparable to Gossypol.
cence polarization assays, and cell-based assays, we
have designed and characterized a novel proapoptotic
Resultscompound targeting these proteins. Our compound,
Apogossypol, is capable of binding and inhibiting Bcl-2
Design, Synthesis, and Biophysicaland Bcl-XL with high affinity and induces apoptosis of
Characterization of Apogossypoltumor cell lines. Mechanistic studies on the action
To solve the problems attributable to the presence ofof our compound were also performed via confocal
the two aldehydes in Gossypol, we synthesized andmicroscopy that provided real-time detection of the
tested novel derivatives of Gossypol (Figure 1). We per-interaction with Bcl-XL in intact cells. Finally, prelimi-
formed in silico docking studies with FlexX softwarenary data on cells freshly isolated from patients af-
using the three dimensional structure of Bcl-XL and afected by chronic lymphocytic leukemia strongly sug-
small library of Gossypol derivatives in which the alde-gest potential applications of Bcl-2 antagonists as
hyde functionalities are replaced. We docked eight dif-chemosensitizers in cancer therapy.
ferent compounds and among these, Apogossypol, a
devised analog of Gossypol missing the two aldehydeIntroduction
groups, gave the lowest binding energy. Although other
derivatives were in the same energy range, the choiceProgrammed cell death plays an essential role in normal
of Apogossypol was also driven by criteria of synthetictissue homeostasis, ensuring a proper balance of cell
accessibility and novelty. In fact, many Gossypol ana-production and cell loss. Defects in the regulation of
logs reported in literature are based on direct derivatiza-programmed cell death promote tumorigenesis, and
tion of the aldehyde functionalities to give Schiff-basealso contribute significantly to chemoresistance [1, 2].
compounds, which can retain certain reactivity. Apogos-Bcl-2-family proteins are central regulators of apoptosis
sypol was predicted to dock with a binding energy com-[3–5]. Overexpression of antiapoptotic Bcl-2-family pro-
parable to Gossypol (36 kcal/mol versus30 kcal/molteins Bcl-2 or Bcl-XL occurs during the pathogenesis or
of Gossypol) in the deep hydrophobic groove on theprogression of most cancers and leukemias. Among all
surface of Bcl-XL that is known to be the same sitegenes studied to date in the NCI’s panel of 60 human
targeted by endogenous antagonists of this protein (Fig-tumor cell lines, Bcl-XL shows the strongest correlation
ure 1C). The low energy conformations of Gossypol andwith resistance to cytotoxic anticancer drugs [6]. Fur-
Apogossypol are similar and the slight steric hindrancethermore, a wide variety of gene transfer, antisense,
of the aldehydes in Gossypol accounts for the slightlypeptide inhibitor, and other types of functional experi-
lower binding energy of Apogossypol. In contrast, Apo-ments have confirmed important roles for Bcl-2 and
gossypol hexaacetate (Figure 1B) failed to bind Bcl-XLBcl-XL in preventing tumor cell apoptosis, validating
in these modeling studies due to steric hindrance of thethese proteins as drug-discovery targets.
acetate groups and was used as a negative control inAlready, antisense oligonucleotides targeting mRNAs
our studies.encoding Bcl-2 have advanced into late-stage clinical
We synthesized Apogossypol in a one-step reaction
by heating Gossypol in presence of 40% NaOH (Figure*Correspondence: mpellecchia@burnham.org (M.P.), jreed@burnham.
1B) [15]. To verify and characterize the binding of Apo-org (J.C.R.)
3These authors contributed equally to this work. gossypol to Bcl-XL, we employed NMR-based binding
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Figure 1. Molecular Modeling Studies and Analog Synthesis
(A) Chemical reaction for the conversion of Gossypol to Apogossypol.
(B) Chemical structure of Apogossypol hexaacetate.
(C) Surface representation of Bcl-xL with the docked structure of Apogossypol obtained by FlexX.
(D) Detail of the docked structure of Apogossypol.
assays and fluorescence polarization displacement Thus, our modification of Gossypol reduced its affinity
for Bcl-XL, but still retained comparable affinity againstassays (FPAs). We first proved by NMR that Apogossy-
pol binds to Bcl-XL by measuring the changes in relax- the target compared to other synthetic compounds pre-
viously described [21–23].ation rates of our ligand in presence of recombinant
purified Bcl-XL protein. T1 experiments [16] of a sample
containing 100 M Apogossypol showed a complete Confocal Microscopic Studies
To determine whether Apogossypol binds Bcl-XL inloss of the protonic signals upon addition of 10 M
Bcl-XL (Figure 2A), which is an indication of binding in intact tumor cells, we devised a cell-based protein inter-
action assay using a green fluorescent protein (GFP)-the low micromolar range [17].
To identify the amino acids involved in the binding tagged protein that contains a BH3 peptide (GFP-Bcl-
Gs) [24]. Accordingly, low passage HeLa cells werewith Bcl-XL, we produced uniformly 15N-labeled Bcl-XL
protein, and performed 2D [15N, 1H]-TROSY NMR spec- transfected with plasmids encoding either wild-type
Bcl-XL or a mutant of Bcl-XL designed to lack reactivitytroscopy [18, 19]. This experiment permits mapping of
the interactions upon addition of compound ligand via with Apogossypol, R139M-Bcl-XL, together with GFP-
Bcl-GS at a ratio of 10:1. The resulting cells were treatedchemical shift perturbation. In particular, addition of
Apogossypol to Bcl-XL (from 1:2 to 2:1 molar ratios) 2 days later with Apogossypol, monitoring the spatial
displacement of GFP-Bcl-Gs (a soluble protein) fromresulted in chemical-shifts or disappearance of several
resonances in the Bcl-XL spectrum (Figure 2B). The resi- its docking sites on mitochondrial Bcl-XL by confocal
microscopy using video time-lapse photography. Thedues most affected by Apogossypol binding are located
in the same pocket of Bcl-XL that is known to bind the fluorescence intensity was quantified over regions of
the transfected cells corresponding to mitochondria,BH3 peptides of endogenous Bcl-XL antagonist pro-
teins. Some changes however can also be observed for where Bcl-XL localizes, before and at various times
after addition of Apogossypol (10 M). As seen in Figureresidues placed in a larger area surrounding this pocket
(Figure 2D). 3A, punctuate mitochondrial fluorescence was dis-
placed by the compound within 2.5 min in cells express-To evaluate the inhibitory properties of Apogossypol
for Bcl-XL, we employed a competitive fluorescence po- ing wild-type Bcl-XL. In contrast, no displacement was
observed with R139M-Bcl-XL transfected cells (Figurelarization assay (FPA), in which the displacement of a
fluorescein-labeled BH3 peptide is monitored upon titra- 3B). Similarly, no GFP-Bcl-GS displacement from wild-
type-Bcl-XL was observed with the control compoundtion of compound [20]. Apogossypol was able to dis-
place fluorescein-labeled BH3 peptide from Bcl-XL with Apogossypol hexaacetate (not shown).
a Ki of 2.3 M (96% confidence interval: 1.18 to 4.37;
Figure 2C, solid squares). In our earlier studies of the Cell-Based Viability Assays
To assess the effects of Gossypol and Apogossypolparent compound, Gossypol, we found that the natural
product displaced the same FITC-BH3 peptide with a on apoptosis, we studied a leukemia cell line 380 that
contains at (14;18) translocation activating the Bcl-2Ki of 0.3 M (96% confidence interval: 0.27 to 0.45).
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Figure 2. NMR Binding Studies and Fluorescence Polarization Assays
(A) T1 experiments (200 ms relaxation time) of free Apogossypol (blue) and Apogossypol in presence of Bcl-XL (red). Asterisks indicate
impurities from protein buffer.
(B) Superposition of [15N, 1H]-TROSY spectra of free Bcl-XL (250 M) (black) and Bcl-XL after addition of Apogossypol (125 M) (red).
(C) Fluorescence polarization-based competitive binding assays (FPA) using a fluorescein-labeled BH3 peptide from the Bad protein (NLWAAQ
RYGRELRRMSD-K(FITC)–FVD) (Synpep Corporation, Dublin, CA) in complex with Bcl-XL are shown for Apogossypol (solid squares) and
Apogossypol hexaacetate (open squares).
(D) Chemical-shift mapping of Apogossypol into the three-dimensional structure of Bcl-XL in complex with Bak peptide. The peptide is displayed
in yellow. Regions affected by the binding of Apogossypol are shown in red.
gene. The effect of Apogossypol and Gossypol on leuke- was induced in a dose-dependent manner by the combi-
nation of these agents (Figure 4B shows representativemia cell viability was evaluated by staining with Annexin
V-FITC/propidium iodide (PI), followed by flow-cytome- data).
try analysis. Both Apogossypol and Gossypol induced
apoptosis of 380 cells in a dose-dependent manner (Fig- Discussion
ure 4A). In contrast, Apogossypol hexaacetate was inac-
tive in these apoptosis assays, in agreement with our The recent discovery of small-molecule chemical com-
pounds capable of binding Bcl-2 and Bcl-XL at micromo-docking studies and fluorescence polarization assay re-
sults for this compound. lar concentrations in vitro and overcoming their protec-
tive effects in the cultured tumor cells has suggested aTo further explore anticancer activities of Apogossy-
pol, we tested its cytotoxicity against primary leukemic new approach to cancer treatment [13, 21–23]. Among
all small-molecule inhibitors described to date, Gossy-cells freshly isolated from 12 different patients affected
by chronic lymphocytic leukemia (CLL). Among them, 9 pol binds Bcl-XL with the highest affinity, suggesting
that it may provide an attractive path forward for designpatients were untreated, while 3 patients had been treated
with conventional chemotherapeutic agents, developing of chemical antagonists of Bcl-2 and Bcl-XL.
Gossypol has been shown to suppress tumor cellrefractory disease (Rai stage 0: 3 cases, Rai stage 1: 2
cases, and Rai stage 2: 7 cases). growth and promote apoptosis of human tumor cell lines
tested in vitro [25–29]. This natural product displaysConsiderable variability in apoptotic responses to
Apogossypol was observed, reflecting heterogeneity of antitumor activity in tumor xenograft studies in mice,
and has been tested in human clinical trials involvingthis disease. Apogossypol induced apoptosis of 6 of the
9 treatment naı¨ve CLL samples, with an LD50 of approxi- patients with advanced malignancies [27, 30–33]. Gos-
sypol has also been used as a male contraceptive agentmately 16 M. However, when used in combination with
a conventional cytotoxic anticancer drug, F-ara-A (the in China for centuries. However, several side-effects of
Gossypol limit its usefulness [27], probably due to theactive metabolite of fludarabine), Apogossypol dis-
played synergistic effects in a subset of CLL patients, presence of two reactive aldehydes in its structure.
Thus, it is reasonable to speculate that these highlyincluding 2 of the 3 fludarabine-refractory CLL speci-
mens. Thus, while neither Apogossypol nor F-ara-A indi- reactive groups, which are known to participate in
Schiff’s base-type reactions with primary amines of pro-vidually induced apoptosis of these CLL cells, apoptosis
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Figure 3. Confocal Microscopy Studies
(A) HeLa cells were transfected with plasmids encoding GFP-Bcl-GS and either wild-type Bcl-XL (left) or mutant Bcl-XL (R139M) (right). After
two days, cells were stained with Mitotracker Red to locate mitochondria. Cells were imaged before (top) and 2.5 min after (bottom) Apogossypol
addition. Panels show fluorescence data collected with red-specific (left) or green-specific (middle) filters, and the overlay of those images
(right). Note that Apogossypol caused displacement of GFP-Bcl-GS from mitochondria in Bcl-XL-expressing but not Bcl-XL (R139M)-expressing
cells.
(B) Fluorescence decay in control and treated wild-type Bcl-XL and R139M-Bcl-XL cells. The measurements revealed the exponential character
of the fluorescence decay after Apogossypol addition in Hela cells expressing Bcl-XL but not the R139M mutant of Bcl-XL. (Purple, wt-Bcl-XL
control; red, wt-Bcl-XL  10 M Apogossypol; green, R139M-Bcl-XL control; and blue, R139M-Bcl-XL  10 M Apogossypol).
teins and nucleic acids, interfere with the compound’s these structure-activity relationship (SAR) studies were
severely limited by lack of knowledge of the cancer-stability in vivo. Thus, these aldehyde functionalities are
likely to be a major cause of the adverse side-effects relevant molecular target of Gossypol. In the present
study, we were aided by the knowledge of the molecularof Gossypol in vivo, causing it to react indiscriminately
with nucleic acids and proteins in tissues. target(s) of Gossypol and by the model of our docked
structure to perform virtual modifications of the com-Several attempts were made in the last decade to
overcome such undesirable side effects [26, 34–36], but pound. The simplest modification that is predicted to
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Figure 4. Cell-Based Assays
(A) The effect of Apogossypol (solid circles),
Gossypol (solid triangles), and Apogossypol
hexaacetate (open circles) on cell viability of
the 380 cell line.
(B) Cytotoxicity of Apogossypol against cul-
tured CLL cells when tested alone (open cir-
cles) and in combination with 10 M F-ara-A
(solid circles). For all points a mean value is
shown. The standard error was  2%.
retain the inhibitory activity of Gossypol is the removal of adult leukemia in North America and Europe. Overex-
pression of Bcl-2 protein is one of the most consistentits aldehyde functionalities to give Apogossypol. When
synthesized and subsequently tested, Apogossypol re- and prominent etiological factors associated with this
disease. CLL often progresses to chemorefractory dis-tained inhibitory activity in vitro against Bcl-XL, although
with a somehow reduced affinity. However, our apopto- ease, indicating a need for novel approaches. Our data
support the idea that Apogossypol is capable of neu-sis assays with cell lines indicate that Apogossypol elic-
its cell death at similar concentrations compared to par- tralizing cytoprotective effects of Bcl-2, acting as che-
mosensitizer. Indeed Apogossypol and F-ara-A can actent compound Gossypol. Thus, while Apogossypol is
less potent than Gossypol at inhibition of the isolated in a synergistic manner, whereby Apogossypol reverses
chemoresistance through its effects on Bcl-2.Bcl-XL protein, the nonreactive, more drug-like charac-
teristics of Apogossypol presumably result in more ef- Thus, taken together, our data strongly suggest that
Apogossypol may be a useful therapeutic agent for thefective delivery of the compound to the target molecule
in intact cells. Consequently, the relative loss of inhibi- treatment of CLL and other malignancies linked to over-
expression of Bcl-2 or Bcl-XL, where chemorefractorytory activity of Apogossypol in vitro is largely compen-
sated by its improved chemical physical properties and states represent a barrier to successful eradication of
cancer.selectivity for Bcl-XL. In fact, in vitro NMR studies con-
ducted in our laboratory show that while Gossypol is
not stable in buffered solutions for more than one or Significance
two days, Apogossypol is stable at the same conditions
for many days. In this context, sperm lactate dehydroge- Altered expression of Bcl-2-family proteins plays a
nase (LDH) is a known target of Gossypol, linked to its central role in apoptosis dysregulation in cancer and
utility as a male contraceptive. We found that Apogos- leukemia, promoting malignant cell expansion and
sypol is much less active compared to Gossypol against contributing to chemoresistance. Previously, the natu-
sperm LDH (not shown), further supporting our hypothe- ral polyphenol Gossypol was found to have cytotoxic
sis that Apogossypol is a more selective inhibitor of activity against several carcinoma cell lines. We re-
Bcl-XL. cently discovered that Bcl-2 and Bcl-XL are targets of
To gain further insight into the mechanism of action Gossypol, providing a potential molecular basis for the
of our compound we introduced mutations in the Bcl-XL observed proapoptotic activity of this natural product
protein by site-directed mutagenesis (namely R139M), and setting the stage for design of analogs with im-
which was predicted on the basis of our model to abolish proved properties. Here, we describe the design, syn-
the interaction with Apogossypol. For this purpose we thesis, and characterization of a nonreactive compound
devised a cell-based assay using a GFP-tagged Bcl-Gs analog lacking the two highly reactive aldehydes, and
protein and monitored the displacement by Apogossy- thus having better drug-like properties. Our compound
pol via time-lapsed confocal microscopy. The data analog, Apogossypol, induces apoptosis of tumor cell
clearly show that punctuate mitochondrial fluorescence lines at concentrations comparable to parent com-
was displaced by Apogossypol in cells expressing wild- pound Gossypol and demonstrates the potential appli-
type Bcl-XL, whereas no displacement was observed cations of Bcl-2 antagonists in cancer chemotherapy.
with R139M-Bcl-XL transfected cells, as predicted. Fi-
Experimental Proceduresnally, fluorescence polarization displacement data with
this mutant indicate a reduction in activity for Apogossy-
Molecular Modelingpol, although affinity for the FITC-BH3 peptide is also
Molecular modeling studies were conducted on several R12000 SGI
decreased, thus making a quantitative comparison unat- Octane workstations with the software package Sybyl version 6.9
tainable with this method. (TRIPOS). The docked structure of Apogossypol was initially ob-
tained by FlexX [37] as implemented in Sybyl. The average scoringThe cytotoxicity data of Apogossypol against primary
function for the 30 best solutions was only slightly lower when theleukemic cells freshly isolated from patients affected by
side-chains were free to rotate. The position of the side-chains inchronic lymphocytic leukemia (CLL) strongly suggest
the model did not change substantially from the initial values. Thepotential applications of selective Bcl-2/XL antagonists resulting best scoring structures were subsequently energy mini-
as chemosensitizers. CLL is a quintessential example mized by using the routine DOCK of SYBYL keeping the site rigid.
of a human malignancy caused by defective programmed The energy of the ligands after the DOCK minimization was within 5
kcal/mol from their global minimum of energy. Color figures showingcell death [3], representing the most common form of
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three-dimensional structures were prepared with the programs without serum in a second tube. Precomplexed DNA and diluted
Lipofectamine reagent were mixed and incubated for 15 min. TheSYBYL and MOLCAD [38].
medium was replaced with 0.8 ml of OPTIMEM without serum. Then,
the DNA-plus-Lipofectamine reagent complexes were added toChemistry
each well of cells containing fresh medium, mixed gently, and incu-Apogossypol was obtained by heating racemic Gossypol acetic acid
bated at 37C at 5% CO2 for 4 hr. After 4 hr, an equal volume of(SIGMA, 150 mg, 0.26 mmol) and 1.5 ml 40% NaOH at 90C for 4 hr.
DMEM  10% FCS was added to each well. On the following day,The reaction mixture was poured into ice containing concentrated
HeLa cells were transferred to glass bottom MatTek dishes (Part #H2SO4 and the aqueous phase was extracted with Et2O. The organic
P35GC-1.5-10-C, -irradiated, poly-d-lysine coated, MatTek Corpo-phase was dried and the solvent evaporated to give crude Apogos-
ration, Ashland, MA).sypol (170 mg, 81% yield) as a racemic mixture of () and ()
The time-lapsed imaging was performed using laser-scanningisomers. 1H NMR (DMSO-d, 500 MHz): 7.41 (s, 2H), 7.38 (s, 2H), 3.38
confocal microscope MRC 1024-MP (Bio-Rad) equipped with ther-(m, 2H), 1.94 (s, 6H), and 1.45 (t, J  6.8, 12H). 13C NMR (DMSO-d,
mostage (Warner Instruments). The images were collected with the500 MHz): 149.7, 144.6, 145.0, 132.6, 128.5, 124.7, 119.5, 115.9,
60	, 1.4 N.A., oil immersion objective lens. The intensity of fluores-103.3, 21.5, 20.5, and 15.6 [39]. Proton chemical shifts in D2O buffer
cence of mitochondrial GFP-Bcl-Gs excited with a 488 nm laser linewere slightly different.
was registered with emission filter 525/35 and measured with the
MetaMorph, v.6.1.2 software (Universal Imaging Co.). All measure-NMR Spectroscopy
ments were taken from sites carrying colocalized signals from theT1 experiments and 2D [15N, 1H]-TROSY spectra were performed
GFP-BCL-Gs and the Mitotracker red CMXRos (Molecular Probes)with a 500 MHz Bruker Avance spectrometer, equipped with three rf
excited with a 568 nm laser line. Confocal images were acquiredchannels and z-axis pulse-field gradients. T1 series were performed
every 30 s up to 10 min. HeLa cells were chosen for this experimentwith a spin-lock pulse of variable length (1 ms, 100 ms, and 200 ms)
because endogenous levels of Bcl-XL are extremely low, allowingwith 100 M compounds in the absence and presence of 10 M
us to detect the effects of transfected Bcl-XL wild-type versus mu-protein. 2D [15N, 1H]-TROSY was measured by titrating Apogossypol
tant Bcl-XL in response to Apogossypol.to 250 M 15N-labeled Bcl-XL dissolved in H2O/D2O (9:1) phosphate
buffer (40 mM) (pH  7.5). Apogossypol was soluble in aqueous
buffer up to 500 M and its solubility is comparable to that of Cell Culture and Apoptosis Assay
Gossypol. 15N-labeled and unlabeled Bcl-XL were expressed and 380 lymphoma cells were cultured at 1 	 106/ml in RPMI containing
purified as previously described [40]. The three-dimensional struc- 10% fetal calf serum (FCS), 1 mM L-glutamine and antibiotics. At
ture of Bcl-XL in complex with Bak peptide (PDB code 1BXL) [40] least 5 	 105 cells were recovered by centrifugation for evaluation
was used for chemical shift mapping and docking studies. In all of percentage apoptotic cells using double staining with Annexin
experiments, dephasing of residual water signals was obtained with V-FITC/PI, followed by flow-cytometry analysis using the FL-1 and
a WATERGATE sequence. FL-3 channels of a flow cytometer (Becton Dickinson; FACSort;
San Jose, CA). B-CLL cells were cultured at 2 	 106/ml in IMDM
Fluorescence Polarization Assays containing 20% fetal calf serum (FCS), 1 mM L-glutamine, and antibi-
Fluorescence polarization assays (FPA) were conducted with a fluo- otics. At least 5 	 105 cells were recovered by centrifugation for
rescein-labeled Bad peptide (NLWAAQRYGRELRRMSD-K(FITC)– evaluation of percentage apoptotic cells using double-staining with
FVD) (Synpep Corporation, Dublin, CA) using an LJL Analyst HT Annexin V-FITC/PI, followed by flow-cytometry analysis using the
(Molecular Devices Co., Sunnyvale, CA). Dilution buffer for all stocks FL-1 and FL-3 channels of a flow cytometer (Becton Dickinson;
and samples was 50 mM phosphate buffer (pH 7.4). A series of 2-fold FACSort; San Jose, CA). Experiments were performed three times
dilutions of Apogossypol were prepared, i.e., 100 M, 50 M, down and FACS data were acquired in duplicate. Experiments were repro-
to 0.1 M in dilution buffer. To each tube was added a solution ducible with deviations of  2%.
containing 120 nM of Bcl-XL and 4 nM fluoresceinated peptide. The
tubes were incubated for 5 min at room temperature,and 20 l Patient Specimens
each of reaction mixture was transferred to 96-well black PS, HE Heparinized pheripheral blood was obtained from patients diag-
Microplate (LJL Biosystems Co.). All assays were performed in nosed with B-CLL according to standard criteria [41]. Lymphocytes
quadruplicate, with blank wells receiving no Apogossypol. Then, were isolated by Ficoll density-gradient centrifugation and verified
the plate was read for total intensity and polarization (in mP units) by immunofluorescence flow cytometry to be composed of 
95%
was measured. Controls included dose-responses measurements CD5/CD19/CD23 triple-positive B cells. Patient’s informed consent
in absence of the proteins, to assess any interactions between the was obtained prior to initiation of this study. The study protocol
compounds and the FITC-BH3 peptide and the compound Apogos- was approved by IRB at UCSD.
sypol hexaacetate, predicted not to interact with Bcl-XL. Approxi-
mate Ki values were obtained according to the following equation:
AcknowledgmentsKi  IC50/(1 [Bcl-XL]/Kd), where Kd is the dissociation constant for
the FITC-BH3 peptide derived from a titration of Bcl-XL in the same
All CLL patient samples were acquired through CRC (CLL ResearchFP assay. Two-way ANOVA analysis was performed to evaluate the
Consortium, Director: Thomas J. Kipps, MD, PhD): Laura Rassenti,differences between Gossypol and Apogossypol: F ratio for curve
PhD, Director of tissue core CLL research consortium, University ofeffect  5.658417, p  0.05.
California, San Diego, 9500 Gilman Drive, La Jolla, CA. We acknowl-
edge the National Cancer Institute (CA 78040, CA 30991 to J.C.R.),Confocal Microscopy
Cap-Cure, and the William R. Hearst Foundation for generous sup-Low-passage HeLa cells (between 10th and 12th passages) were
port. M.L. thanks the Universita’ degli Studi di Napoli “Federico II,”transfected with wild-type Bcl-XL or mutant Bcl-XL R139M plasmid
Italy for a fellowship. We also thank Dr. Erwin Goldberg (Northwest-and GFP-Bcl-Gs at a ratio of 10: 1 (typically, 2.7 g of Bcl-XL plasmid
ern University) for kindly testing our compounds against sperm LDH.and 0.3 g GFP-Bcl-Gs) using Lipofectamine plus reagent (In-
vitrogen Cat. No. 11514-015). These cells were chosen because they
Received: September 29, 2003are highly transfectable and contain only low levels of endogenous
Revised: November 21, 2003Bcl-XL. Briefly, HeLa cells were plated in 6-well plates the day before
Accepted: December 22, 2003transfection so that they were 50%–80% confluent on the day of
Published: March 19, 2004transfection. The DNA and the Plus reagent were precomplexed: a
total of 3 g of plasmid DNA was diluted into 100 l of Dulbecco’s
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